BACKGROUND:Perinatal major depressive disorder (MDD), including antenatal and postpartum depression, is common and has serious consequences. This study was designed to investigate the feasibility, safety, and efficacy of omega-3 fatty acids for perinatal depression in addition to supportive psychotherapy. METHODS:Perinatal women with MDD were randomized to eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), 1.9g/day, or placebo for 8weeks. A manualized supportive psychotherapy was provided to all subjects. Symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D) and Edinburgh Postnatal Depression Scale (EPDS) biweekly. RESULTS:Fifty-nine women enrolled; N = 51 had two data collection points that allowed for evaluation of efficacy. Omega-3 fatty acids were well tolerated. Participants in both groups experienced significant decreases in EPDS and HAM-D scores (p<.0001) from baseline. We did not find a benefit of omega-3 fatty acids over placebo. Dietary omega-3 fatty acid intake was low among participants. LIMITATIONS: The ability to detect an effect of omega-3 fatty acids may have been limited by sample size, study length, or dose. The benefits of supportive psychotherapy may have limited the ability to detect an effect of omega-3 fatty acids. CONCLUSIONS: There was no significant difference between omega-3 fatty acids and placebo in this study in which all participants received supportive psychotherapy. The manualized supportive psychotherapy warrants further study. The low intake of dietary omega-3 fatty acids among participants is of concern, in consideration of the widely established health advantages in utero and in infants.
RCT Entities:
BACKGROUND: Perinatal major depressive disorder (MDD), including antenatal and postpartum depression, is common and has serious consequences. This study was designed to investigate the feasibility, safety, and efficacy of omega-3 fatty acids for perinatal depression in addition to supportive psychotherapy. METHODS: Perinatal women with MDD were randomized to eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), 1.9g/day, or placebo for 8weeks. A manualized supportive psychotherapy was provided to all subjects. Symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D) and Edinburgh Postnatal Depression Scale (EPDS) biweekly. RESULTS: Fifty-nine women enrolled; N = 51 had two data collection points that allowed for evaluation of efficacy. Omega-3 fatty acids were well tolerated. Participants in both groups experienced significant decreases in EPDS and HAM-D scores (p<.0001) from baseline. We did not find a benefit of omega-3 fatty acids over placebo. Dietary omega-3 fatty acid intake was low among participants. LIMITATIONS: The ability to detect an effect of omega-3 fatty acids may have been limited by sample size, study length, or dose. The benefits of supportive psychotherapy may have limited the ability to detect an effect of omega-3 fatty acids. CONCLUSIONS: There was no significant difference between omega-3 fatty acids and placebo in this study in which all participants received supportive psychotherapy. The manualized supportive psychotherapy warrants further study. The low intake of dietary omega-3 fatty acids among participants is of concern, in consideration of the widely established health advantages in utero and in infants.
Authors: J A McGregor; K G Allen; M A Harris; M Reece; M Wheeler; J I French; J Morrison Journal: Obstet Gynecol Surv Date: 2001-05 Impact factor: 2.347
Authors: K L Wisner; D A Zarin; E S Holmboe; P S Appelbaum; A J Gelenberg; H L Leonard; E Frank Journal: Am J Psychiatry Date: 2000-12 Impact factor: 18.112
Authors: Carol Louik; Angela E Lin; Martha M Werler; Sonia Hernández-Díaz; Allen A Mitchell Journal: N Engl J Med Date: 2007-06-28 Impact factor: 91.245
Authors: S J Otto; A C Houwelingen; M Antal; A Manninen; K Godfrey; P López-Jaramillo; G Hornstra Journal: Eur J Clin Nutr Date: 1997-04 Impact factor: 4.016
Authors: Marlene P Freeman; Joseph R Hibbeln; Katherine L Wisner; John M Davis; David Mischoulon; Malcolm Peet; Paul E Keck; Lauren B Marangell; Alexandra J Richardson; James Lake; Andrew L Stoll Journal: J Clin Psychiatry Date: 2006-12 Impact factor: 4.384
Authors: Christina D Chambers; Sonia Hernandez-Diaz; Linda J Van Marter; Martha M Werler; Carol Louik; Kenneth Lyons Jones; Allen A Mitchell Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Emily Oken; Ken P Kleinman; Wendy E Berland; Steven R Simon; Janet W Rich-Edwards; Matthew W Gillman Journal: Obstet Gynecol Date: 2003-08 Impact factor: 7.661
Authors: Ellen L Mozurkewich; Chelsea M Clinton; Julie L Chilimigras; Susan E Hamilton; Lucy J Allbaugh; Deborah R Berman; Sheila M Marcus; Vivian C Romero; Marjorie C Treadwell; Kristie L Keeton; Anjel M Vahratian; Ronald M Schrader; Jianwei Ren; Zora Djuric Journal: Am J Obstet Gynecol Date: 2013-04 Impact factor: 8.661
Authors: David Mischoulon; George I Papakostas; Christina M Dording; Amy H Farabaugh; Shamsah B Sonawalla; A Monica Agoston; Juliana Smith; Erin C Beaumont; Liat E Dahan; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava Journal: J Clin Psychiatry Date: 2009-08-25 Impact factor: 4.384